Yazar "Çakır, Erkan" için listeleme
-
CFTR mutations unidentified in CFTR2 database and their phenotypic characteristics: Data from cystic fibrosis registry of Turkey
Cinel, Güzin; Doğru, Deniz; Çakır, Erkan; Eyüboğlu, Tuğba Şişmanlar; Çobanoğlu, Nazan; Pekcan, Sevgi; Yalçın, Ebru; Can, Demet (European Respiratory Soc Journals Ltd, 2020)Abstract Background: Cystic Fibrosis Registry of Turkey shows various CFTR mutations due to the geographical location and historical background of our country, and also high prevalence of consanguineous marriages. Method:All ... -
Clinical features and accompanying findings of Pseudo-Bartter Syndrome in cystic fibrosis
Eyüboğlu, Tuğba Şişmanlar; Doğru, Deniz; Çakır, Erkan; Çobanoğlu, Nazan; Pekcan, Sevgi; Cinel, Güzin; Yalçın, Ebru; Can, Demet (Wiley, 2020)Background Pseudo-Bartter syndrome (PBS) is a rare complication of cystic fibrosis (CF) and there are limited data in the literature about it. We aimed to compare clinical features and accompanying findings of patients ... -
Clinical findings of patients with cystic fibrosis according to newborn screening results
Gürsoy, Tuğba Ramaslı; Aslan, Ayşe Tana; Asfuroğlu, Pelin; Eyüboğlu, Tuğba Şişmanlar; Çakır, Erkan; Çobanoğlu, Nazan; Can, Demet (Wiley, 2022)Background Cystic fibrosis (CF) is a lethal recessive genetic disease caused by loss of function associated with mutations in the CF trans-membrane conductance regulator. It is highly prevalent (approximately 1 in 3,500) ... -
Cystic fibrosis in Turkey: First data from the national registry
Doğru, Deniz; Çakır, Erkan; Şişmanlar, Tuğba; Çobanoğlu, Nazan; Pekçan, Sevgi; Çinel, Güzin; Yalçın, Ebru; Can, Demet (Wiley, 2019)Background Cystic fibrosis (CF) care has been implemented in Turkey for a long time; however, there had been no patient registry. For this purpose, the Turkish National CF Registry was established. We present the first ... -
Cystic fibrosis patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey
Çobanoğlu, Fatma Nazan; Ersöz, Deniz Doğru; Çakır, Erkan; Eyuboğlu, Tuğba; Pekcan, Sevgi; Cinel, Güzin; Yalçın, Ebru; Can, Demet (European Respiratory Soc Journals Ltd, 2019)Better understanding of CFTR biology has led to the development of modulator drugs. Lumacaftor/Ivacaftor (L/T) is approved for people ages ≥2 who have two copies of the F508del mutation. Tezacaftor/Ivacaftor (T/I) is ... -
Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey
Çobanoğlu, Fatma Nazan; Özçelik, Uğur; Çakır, Erkan; Eyüboğlu, Tuğba Şişmanlar; Pekcan, Sevgi; Cinel, Güzin; Yalçın, Ebru; Can, Demet (Wiley, 2020)Background A better understanding of cystic fibrosis transmembrane conductance regulator biology has led to the development of modulator drugs such as ivacaftor, lumacaftor-ivacaftor, tezacaftor-ivacaftor, and elexacafto ...
